Logo image of EYEN

EYENOVIA INC (EYEN) Stock Fundamental Analysis

NASDAQ:EYEN - Nasdaq - US30234E2037 - Common Stock - Currency: USD

2.03  +0.63 (+45%)

After market: 1.85 -0.18 (-8.87%)

Fundamental Rating

1

Overall EYEN gets a fundamental rating of 1 out of 10. We evaluated EYEN against 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of EYEN have multiple concerns. EYEN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EYEN has reported negative net income.
EYEN had a negative operating cash flow in the past year.
In the past 5 years EYEN always reported negative net income.
EYEN had a negative operating cash flow in each of the past 5 years.
EYEN Yearly Net Income VS EBIT VS OCF VS FCFEYEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of EYEN (-1358.27%) is worse than 96.46% of its industry peers.
Industry RankSector Rank
ROA -1358.27%
ROE N/A
ROIC N/A
ROA(3y)-514.41%
ROA(5y)-328.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EYEN Yearly ROA, ROE, ROICEYEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

EYEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EYEN Yearly Profit, Operating, Gross MarginsEYEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200K -400K -600K

More info and screens

0

2. Health

2.1 Basic Checks

EYEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EYEN has been increased compared to 1 year ago.
The number of shares outstanding for EYEN has been increased compared to 5 years ago.
Compared to 1 year ago, EYEN has a worse debt to assets ratio.
EYEN Yearly Shares OutstandingEYEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
EYEN Yearly Total Debt VS Total AssetsEYEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

EYEN has an Altman-Z score of -112.50. This is a bad value and indicates that EYEN is not financially healthy and even has some risk of bankruptcy.
EYEN has a worse Altman-Z score (-112.50) than 93.94% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -112.5
ROIC/WACCN/A
WACC12.38%
EYEN Yearly LT Debt VS Equity VS FCFEYEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M -30M

2.3 Liquidity

A Current Ratio of 0.17 indicates that EYEN may have some problems paying its short term obligations.
EYEN's Current ratio of 0.17 is on the low side compared to the rest of the industry. EYEN is outperformed by 94.95% of its industry peers.
EYEN has a Quick Ratio of 0.17. This is a bad value and indicates that EYEN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.17, EYEN is doing worse than 93.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.17
Quick Ratio 0.17
EYEN Yearly Current Assets VS Current LiabilitesEYEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 4.98% over the past year.
Looking at the last year, EYEN shows a very strong growth in Revenue. The Revenue has grown by 2103.85%.
EYEN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -84.00% yearly.
EPS 1Y (TTM)4.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.88%
Revenue 1Y (TTM)2103.85%
Revenue growth 3Y-84%
Revenue growth 5YN/A
Sales Q2Q%981.08%

3.2 Future

Based on estimates for the next years, EYEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.19% on average per year.
EYEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 135.99% yearly.
EPS Next Y33.51%
EPS Next 2Y21.63%
EPS Next 3Y20.36%
EPS Next 5Y15.19%
Revenue Next Year400.98%
Revenue Next 2Y356.17%
Revenue Next 3Y250.09%
Revenue Next 5Y135.99%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EYEN Yearly Revenue VS EstimatesEYEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
EYEN Yearly EPS VS EstimatesEYEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EYEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EYEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EYEN Price Earnings VS Forward Price EarningsEYEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EYEN Per share dataEYEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40 -50

4.3 Compensation for Growth

A more expensive valuation may be justified as EYEN's earnings are expected to grow with 20.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.63%
EPS Next 3Y20.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EYEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EYENOVIA INC

NASDAQ:EYEN (5/22/2025, 4:48:51 PM)

After market: 1.85 -0.18 (-8.87%)

2.03

+0.63 (+45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners3.36%
Inst Owner Change-93.28%
Ins Owners0.8%
Ins Owner Change0.52%
Market Cap5.74M
Analysts47.5
Price Target163.2 (7939.41%)
Short Float %2.92%
Short Ratio0.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.38%
Min EPS beat(2)5.64%
Max EPS beat(2)19.12%
EPS beat(4)2
Avg EPS beat(4)-10.46%
Min EPS beat(4)-37.25%
Max EPS beat(4)19.12%
EPS beat(8)5
Avg EPS beat(8)-0.95%
EPS beat(12)6
Avg EPS beat(12)0.13%
EPS beat(16)10
Avg EPS beat(16)11.38%
Revenue beat(2)0
Avg Revenue beat(2)-97.77%
Min Revenue beat(2)-98.79%
Max Revenue beat(2)-96.75%
Revenue beat(4)0
Avg Revenue beat(4)-98.16%
Min Revenue beat(4)-99.52%
Max Revenue beat(4)-96.75%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7900%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 100.26
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-50.93
EYN/A
EPS(NY)-33.86
Fwd EYN/A
FCF(TTM)-10.7
FCFYN/A
OCF(TTM)-10.64
OCFYN/A
SpS0.02
BVpS-4.63
TBVpS-4.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1358.27%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-514.41%
ROA(5y)-328.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.31%
Cap/Sales 281.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.17
Quick Ratio 0.17
Altman-Z -112.5
F-Score3
WACC12.38%
ROIC/WACCN/A
Cap/Depr(3y)219.51%
Cap/Depr(5y)330.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.88%
EPS Next Y33.51%
EPS Next 2Y21.63%
EPS Next 3Y20.36%
EPS Next 5Y15.19%
Revenue 1Y (TTM)2103.85%
Revenue growth 3Y-84%
Revenue growth 5YN/A
Sales Q2Q%981.08%
Revenue Next Year400.98%
Revenue Next 2Y356.17%
Revenue Next 3Y250.09%
Revenue Next 5Y135.99%
EBIT growth 1Y-47.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-88.59%
EBIT Next 3Y54.61%
EBIT Next 5Y39.01%
FCF growth 1Y-13.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.36%
OCF growth 3YN/A
OCF growth 5YN/A